SCHEMBL22470134

SCHEMBL22470134

O=C(O)N1CCC[C@H]1CNC1(c2ccc(F)c(C(F)(F)F)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 5/20 0.49
NOTUM Q6P988 1/20 0.40
MCHR1 Q99705 6/20 0.39
CHRM3 P20309 1/20 0.38
AR P10275 1/20 0.37
CYP2D6 P10635 1/20 0.36
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
PDE2A O00408 2/20 0.35
APP P05067 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
HTR1D P28221 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22470069 1.00 KCNN4 (0.49) KCNN4NOTUMMCHR1CHRM3AR
SCHEMBL22470141 1.00 KCNN4 (0.49) KCNN4NOTUMMCHR1CHRM3AR
SCHEMBL22470247 0.94 KCNN4 (0.44) KCNN4NOTUMMCHR1ARPDE2A
SCHEMBL22470251 0.94 KCNN4 (0.44) KCNN4NOTUMMCHR1ARPDE2A
SCHEMBL28648709 0.87 KCNN4 (0.49) KCNN4CHRM3APPHTR1AADRA2A
SCHEMBL28648705 0.87 KCNN4 (0.49) KCNN4CHRM3APPHTR1AADRA2A
SCHEMBL28648706 0.87 KCNN4 (0.49) KCNN4CHRM3APPHTR1AADRA2A
SCHEMBL22470078 0.85 KCNN4 (0.40) KCNN4NOTUMMCHR1
SCHEMBL22470080 0.85 KCNN4 (0.40) KCNN4NOTUMMCHR1
SCHEMBL22470462 0.85 KCNN4 (0.43) KCNN4MCHR1CYP2D6DPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12006289-B2 Potassium channel inhibitors SANIONA A/S (DK) 2024-06-11 US disclosed
CN-113631538-B Novel potassium channel inhibitors 萨尼奥纳有限责任公司 2024-05-31 CN disclosed
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2022-06-02 US disclosed
EP-3941903-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Saniona A/S (DK) 2022-01-26 EP disclosed
WO-2020193419-A1 NOVEL POTASSIUM CHANNEL INHIBITORS SANIONA A/S (DK) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169602-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN2, KCNJ2, KCNN1 KCNN4 57/4885NOTUM 4389/4885MCHR1 4050/4885
US-12006289-B2 Potassium channel inhibitors KCNJ2, KCNN2, KCNN1 KCNN4 48/4885NOTUM 3646/4885MCHR1 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.